Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients-Reference-Cited by-同舟云学术

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

Published:2015-10 Issue:10 Volume:39 Page:1055-1059
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Breccia Massimo,Efficace Fabio,Sica Simona,Abruzzese Elisabetta,Cedrone Michele,Turri Diamante,Gobbi Marco,Carella Angelo Michele,Gozzini Antonella,Usala Emilio,Cavazzini Francesco,Danise Paolo,Tiribelli Mario,Binotto Gianni,Pregno Patrizia,Bocchia Monica,Gaidano Gianluca,Crugnola Monica,Bonifacio Massimiliano,Avanzini Paolo,Celesti Francesca,Guella Anna,Martino Bruno,Annunziata Mario,Luciano Luigiana,Stagno Fabio,Vallisa Daniele,Pungolino Esther,Iurlo Alessandra,Rambaldi Alessandro,Nardiello Ida,Orlandi Esther,Gambacorti-Passerini Carlo,Alimena Giuliana

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference21 articles.

1. The development of imatinib as a therapeutic agent for chronic myeloid leukemia;Deininger;Blood,2005

2. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study;Hahn;J. Clin. Oncol.,2003

4. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study;Noens;Blood,2009

5. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib;Marin;J. Clin. Oncol.,2010

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF;Leukemia;2024-03-12

2. Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia;Internal Medicine;2024

3. Chronic myeloid leukaemia: A qualitative interview study exploring disease impact from patient and practitioner perspectives;European Journal of Oncology Nursing;2023-12

4. Chronic myeloid leukemia: A qualitative interview study exploring disease impact from patient and practitioner perspectives;2023-08-02

5. Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia;Cancer Medicine;2023-07-06